Latest news and press releases about Quoin Pharmaceuticals, Ltd. (QNRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.
Price
| Price | $6.90 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.52 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -304.87% |
| Return on Invested Capital | -359.18% |
| Return on Assets | -156.71% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CYCN · KTTA · NBY · PLRZ · PMCB · RADX · TCRT
Explore sector: Healthcare · Biotechnology
More sections of QNRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks